Least developed countries vs Malta: Immunization, Hib3
Least developed countries
74.4%
in 2024
Malta
97.0%
in 2024
Least developed countries rank
30th
Malta rank
29th
Immunization, Hib3 over time
- Least developed countries
- Malta
How they compare
Malta currently reports 97.0% against 74.4% in Least developed countries, a difference of 22.6%.
That makes Malta's figure about 1.3 times Least developed countries's.
Across all 29 years both countries report, Malta has been ahead every year.
Least developed countries ranks 30th and Malta ranks 29th of 43 groups.
Malta has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Least developed countries | Malta | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0.1% | 70.5% | 70.4% | Malta |
| 2000s | 16.8% | 81.1% | 64.3% | Malta |
| 2010s | 75.5% | 95.6% | 20.1% | Malta |
| 2020s | 74.4% | 98.0% | 23.6% | Malta |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher immunization, hib3, Least developed countries or Malta?
- Malta, at 97.0% against 74.4% in Least developed countries as of 2024.
- What is the difference in immunization, hib3 between Least developed countries and Malta?
- 22.6%, with Malta ahead.
- How many years of comparable data are there for Least developed countries and Malta?
- 29 years are reported by both, from 1996 to 2024.
- How do Least developed countries and Malta rank globally for immunization, hib3?
- Least developed countries ranks 30th and Malta ranks 29th of 43 groups.
- Where does this data come from?
- WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/), published as Immunization, Hib3 (% of children ages 12-23 months). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Child immunization, Hib3, measures the percentage of children ages 12-23 months who received Hib3 vaccinations before 12 months or at any time before the survey. A child is considered adequately immunized against Hib3 after receiving three doses of Haemophilus influenzae type b vaccine.